Observational analyses and post-hoc evaluations of major CV outcome trials, including DECLARE-TIMI and DAPA-HF, consistently show lower AF event rates among patients receiving SGLT-2 inhibitors. The gene discussed is SLC5A2; the disease is atrial fibrillation.